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Background: Anemia, leucopenia and thrombocytopenia are the commonest hematological abnormalities
resulting from human immunodeficiency virus infection. The use of antiretroviral drugs could positively or
negatively affect these disorders. Thus a specific diagnosis and a determination of hematological and
immunological parameters are required for initiating and monitoring early treatment to avert disease progression.
Therefore, this study aimed to compare hematological and immunological parameters in HIV positive patients
taking antiretroviral therapy and those treatment naïve patients in Gondar University Hospital.
Methods: A comparative cross-sectional study was conducted on a total of 290 HIV patients from February to May
2012 in Gondar University Hospital. Study subjects were divided in to two groups: 145 HIV positive treatment naïve
and 145 on HAART. Data of socio demographic characteristics and clinical conditions of the study subjects was
collected using structured pretested questionnaire at their follow up date. Hematological and immunological
parameters were collected and processed by cell Dyne 1800 and BD FACS count respectively. The variables
compared here were Hematological parameters (Total and differential WBC, RBC, Hgb, HCT, MCV, MCH, MCHC,
RDW, PLT, and MPV) and CD4 count. In order to compare means independent sample T-test was conducted
using SPSS version 20 statistical software. P- Value < 0.05 was considered as significant.
Result: Prevalence of anemia, leucopenia, thrombocytopenia, neutropenia and lymphopenia were 11.7%, 35.9%,
4.1%, 28.3% and 2.1% in patients on HAART and 29.7%, 16.6%, 9%, 14.5% and 2.1% in HAART naïve patients
respectively. There was a significant difference in total WBC, RBC, Hgb, MCV, MCH, MCHC, MPV and CD4 counts
between patients on HAART and HAART naïve patients.
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Conclusion: Prevalence of anemia was high in HAART naïve patients while leucopenia and neutropenia prevalence
was higher in patients on HAART and their prevalence increased as the CD4 count decreased. HIV Patients should
be investigated for hematological and immunological changes following with appropriate therapeutic interventions.
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Hematological abnormalities are common complications
of human immunodeficiency virus infection. These ab-
normalities increase as the disease advances. In both
antiretroviral-treated and untreated individuals, different
types of hematological abnormalities are common [1-3].
Anemia is the most common hematological abnormal-
ities in human immunodeficiency virus (HIV) patients.
Its prevalence ranges from 1.3% to 95%, normocytic nor-
mochromic anemia being the predominant type followed
by microcytic anemia [3-7]. Several factors play a role in
the development of anemia in patients with HIV, includ-
ing chronic disease, opportunistic infections, nutritional
deficiencies and toxicities from medications. As HIV dis-
ease progresses, the prevalence and severity of anemia
also increases [6,8].
Thrombocytopenia is the second most frequent com-
plication of human immunodeficiency virus infection
which is found in 3-40% of individuals with HIV infec-
tion and could occur at any stage of HIV infection.
Chronic infection with HIV is now well-characterized
causes of chronic immune thrombocytopenic purpura
[9]. The possible mechanisms that have been reported
are immune-mediated destruction of platelets by anti-
bodies, cross-reacting antibodies that are directed to-
ward HIV proteins, particularly gp120 and p-24. This
type of platelet destruction is called immune thrombocy-
topenic purpura (ITP) which is characterized by very
low platelet counts with normal hematocrit and white
blood cell count [3,4,10].
Neutropenia is the most common leucopenia occur-
ring in HIV infected individuals. It may occur in 10-30%
of HIV patients with advanced disease [3]. HIV infection
suppresses the bone marrow and leads to decreased
levels of granulocyte colony-stimulating factor, the factor
that stimulates production of white blood cells in the
bone marrow and affects the granulocyte-macrophage
lineage, resulting in leukopenia and neutropenia. Also
myelosuppressive drugs or other opportunistic infections
including cytomegalovirus, tuberculosis, histoplasmosis
and leishmaniasis may cause leucopenia. Furthermore,
HIV infection can directly result in lymphopenia as the
infection progresses, leading to a decrease in CD4+ lym-
phocytes [3,4].
Hematological parameters are important monitoring
tools for assessing treatment and prognosis in HIV. Theuse of antiretroviral drugs could positively or negatively
affect these parameters, depending on the choice of
combination used. Although many drugs used for the
treatment of HIV-related disorders are myelosuppres-
sive, severe cytopenia is most often related to the use of
zidovudine [5].
Despite the presence of few reports on the hematological
parameters of HIV positive individuals in Ethiopia [11,12]
comparative studies between HAART naïve and on
HAART individuals is scarce. This study, therefore,
assessed hematological and immunological parameters in
HIV positive treatment naïve and those on HAART in
ARTclinic of Gondar University Hospital.
Methods
Study setting and study population
A cross-sectional study was conducted at Gondar University
Hospital, Northwest Ethiopia, from February to May 2012.
During the study period there were about 9000 people
leaving with HIV on follow-up care in the ART clinic.
Double proportion population formula was used to deter-
mine the number of study subjects and a total of 290 adult
study subjects, which divided 145 HIV positive treatment
naïve and 145 individuals on HAART for a period of
6 months or more were chosen. Adult HIV positive preg-
nant patients and patients on medication (vitamin supple-
ments and tuberculosis treatment) at the time of sampling
were excluded from the study.
Data collection
Data on the socio-demographic and clinical characteris-
tics of the study participants were collected using a pre-
tested structured questionnaire by interview and review
of medical records. About 4 ml of venous blood was
collected by an experienced laboratory technologist from
each subject for immunological and hematological
parameters analysis. Hematological parameters were
determined using the hematology analyzer Cell-Dyn
1800 (Abbott Laboratories Diagnostics Division, USA)
whereas the immunological (CD4+ T cells) were assayed
using the BD FACSCOUNT system (Becton Dickenson
and Company, California, USA). To ensure good quality
data, pre-testing was done on patients being managed at
the Gondar University Hospital before the study.
The performance of the hematology analyzer and the
BD FACSCOUNT system were controlled by running
Table 1 Characteristics of HIV positive patients at Gondar
University Hospital from February – May 2012
Variables HIV patients
(n = 290)
On HAART
(n = 145)
HAART Naïve
(n = 145)
Age
<25 years 49 (16.9%) 14 (9.7%) 35 (24.1%)
25–35 years 139 (47.9%) 78 (53.8%) 61 (42.1%)
35–45 years 73 (25.2%) 38 (26.2%) 35 (24.2%)
>45 years 29 (10%) 15 (10.3%) 14 (9.7%)
Sex
Male 106 (36.6%) 46 (31.7%) 60 (41.4%)
Female 184 (63.4%) 99 (68.3%) 85 (58.6%)
Residence
Urban 205 (70.7%) 114 (78.6%) 91 (62.8%)
Rural 85 (29.3%) 31 (21.4%) 54 (37.2%)
Marital status
Single 42 (14.5%) 20 (13.8%) 22 (15.2%)
Married 135 (46.6%) 61 (42.1%) 74 (51%)
Divorced 67 (23.1%) 31 (21.4%) 36 (24.8%)
Widowed 46 (15.9%) 33 (22.8%) 13 (9%)
Educational status
Illiterate 64 (22.1%) 30 (20.7%) 34 (23.4%)
Elementary school 95 (32.8%) 47 (32.4%) 48 (33.1%)
Secondary school 90 (31%) 48 (33.1%) 42 (29%)
Certificate and above 41 (14.1%) 20 (13.8%) 21(14.5%)
WHO clinical stage
I 257 (88.6%) 128 (88.3%) 129 (89%)
II 12 (4.1%) 4 (2.8%) 8 (5.5%)
III 20 (6.9%) 12 (8.3%) 8 (5.5%)
IV 1(0.3%) 1 (0.7%) 0
Cotrimoxazole
Yes 116 (40%) 102 (70.3%) 14 (9.7%)
No 174 (60%) 43 (29.7%) 131 (90.3%)
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pant’s sample. In addition, all flagged specimen were
subjected to manual differential to confirm the
results.
Statistical analysis
The data was cleaned, edited, checked for completeness
and processed then entered in to Epi Info version 3.5.3
and transported to SPSS version 20 statistical software.
Independent T test was used to compare means of each
hematological parameter (Total and differential WBC,
RBC, Hgb, HCT, MCV, MCH, MCHC, RDW, PLT, and
MPV) and CD4 count between treatment naïve and
those on HAART. P-value < 0.05 was considered as sta-
tistically significant.
Ethical consideration
Ethical clearance was obtained from the Institutional
Ethics Review Board of the University of Gondar. Per-
mission for the conduct of the study was also obtained
from the University Hospital. After informing study par-
ticipants of the objectives of the study and assuring them
of confidentiality of their data, written informed consent
was taken from all the participants.
Result
General characteristics of the study participants
A total of 290 HIV infected patients which was cate-
gorized in to two, 145 on HAART and 145 HAART
naïve were involved in this study. About 184 (63.4%)
were females (99 on HAART and 85 HAART naïve)
and 106 (36.6%) were males (46 on HAART and 60
HAART naïve). The overall mean age was 34 ± 9.2 years,
within the range of 18 – 72 years of age. Majority of
the patients, 212 (73.1%), were within 25 – 45 years
of age (Table 1).
Hematological and immunological parameters
The mean WBC, Hgb, RBC, PLT and CD4 were 5.2 ±
1.9 ×103/μl, 14 ± 1.6 g/dl, 4 ± 0.6 ×106/μl, 258.6 ± 82.9 and
415.4 ± 218.8 cells respectively in patients on HAART and
6.3 ± 2.3 × 103/μl, 13 ± 2.1 g/dl, 4.7 ± 0.8 × 106/μl, 253.1 ±
95.2 and 361.1 ± 224.4 cells respectively for HAART naïve
patients. WBC, ANC, RBC and MPV count was statistically
higher in HAART naïve patients while Hgb, MCV, MCH,
MCHC, MPV and CD4 count were higher in patients who
were on HAART (Table 2).
Hematological abnormalities
Out of the total number of study participants, 20.7% had
anemia, 26.2% had leucopenia, 6.6% had thrombocytopenia
and 0.7% had pancytopenia. According to WHO classifica-
tion from anemic subjects, 16.7% had moderate anemia
(Hgb = 7-10 g/dl) and 83.3% had mild anemia (Hgb = 10-12 g/dl). The prevalence of anemia in patients who are on
HAART was 11.7% while in HAART naïve patients it was
29.7% (Table 3).
From the total anemic HIV infected individuals, 43.3%
had normocytic-normochromic followed by normocy-
tic-hypochromic (23.3%) and macrocytic-normochromic
(18.3%) anemia. From patients on HAART, 58.8% had
macrocytic normochromic anemia while from HAART-
naïve patients, 48.8% had normocytic-normochromic
anemia (Table 4).
From HIV patients on HAART 58.8% were on Zidovu-
dine (AZT) based therapy and all had macrocytosis. The
remaining 41.2% were non AZT based therapy and 42.8%
of them had normocytic normochromic anemia.
Table 2 Hematological parameters of HIV positive patients at Gondar University Hospital from February – May 2012
Parameters HIV patients (N = 290) On HAART (N = 145) HAART Naïve (N = 145) P-value
(Mean ± SD) Mean ± SD Mean ± SD
WBC (×103/μl) 5.73 ± 2.2 5.2 ± 1.9 6.3 ± 2.3 <0.001
TLC (×103/μl) 2 ± 0.9 1.9 ± 0.9 2 ± 0.9 0.189
ANC (×103/μl) 2.73 ± 1.6 2.4 ± 1.4 3.1 ± 1.7 <0.001
RBC (×106/μl) 4.32 ± 0.8 4 ± 0.6 4.7 ± 0.8 <0.001
Hgb (g/dl) 13.5 ± 1.9 14 ± 1.6 13 ± 2.1 <0.001
PCV (%) 41 ± 5.5 41.4 ± 4.4 40.4 ± 6.4 0.124
MCV (fl) 96.4 ± 11.7 10.5 ± 1 8.8 ± 0.6 <0.001
MCH (pg) 32 ± 5.2 35.3 ± 4.2 28.4 ± 3.7 <0.001
MCHC (g/dl) 33 ± 2.2 33.6 ± 1.8 32.2 ± 2.3 <0.001
RDW (%) 14.6 ± 1.7 14.4 ± 1.8 14.8 ± 1.7 0.052
PLT (×103/μl) 256 ± 89 258.6 ± 82.9 253.1 ± 95.2 0.596
MPV (%) 9.7 ± 1.3 9.4 ± 1 10 ± 1.4 <0.001
CD4 (Cells/μl) 1091.1 ± 592 415.4 ± 218.8 361.1 ± 224.4 0.038
Note: Numerical data in Bold = indicates the level of significance (p < 0.05) when the HAART naïve were compared to those on HAART (unpaired t-test).
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The overall minimum CD4 count was 13 cell/μl and the
maximum was 1336 cells/μl with a median CD4 count of
350 cells/μl and inter-quartile range of 218 – 518 cells/μl.
Twenty percent of the study population had CD4 counts
of < 200 cells and 15.5% of them had CD4 counts < 100
cells. Majority of the study population (54.5%) had CD4
count between 200 and 500 cells. About 25.5% of study
population had CD4 count > 500 cells/μl. Increased
percentage of Anemia, leucopenia and thrombocytopenia
were observed in HIV patients whose CD4 count
was < 200 cells/μl (P < 0.05), but there was no significant
association in the neutropenia between patients who were
categorized in to different CD4 count categories (P > 0.05)
(Table 5).Discussion
Anemia, leucopenia especially neutropenia and throm-
bocytopenia were common findings in the present study.
This was also documented in different studies [1,2,4].
Prevalence of pancytopenia (0.7%) was lower than study
done in India 6% in 2008 [3]. Also Prevalence of anemia
in this study (20.7%) was lower than study done in IndiaTable 3 Hematological disorders in HIV patients at
Gondar University Hospital from February to May 2012
Variable On HAART HAART naive
Anemia 17 (11.7%) 43 (29.7%)
Leucopenia 52 (35.9%) 24 (16.6%)
Thrombocytopenia 6 (4.1%) 13 (9%)
Lymphopenia 3 (2.1%) 3 (2.1%)
Neutropenia 41 (28.3%) 21 (14.5%)in 2002 [7] and 2008 [3] which was 30.8% and 65.5%
respectively, Southern India 41% [13], Brazil 37.5% [14],
Nigeria from 2000–2005 (74%) [15], Nigeria between
June 2002 and July 2003 (80%) [16]. This may be due to
the difference in study population, socio-demographic
characteristics of study subjects and study design
methods.
In this study prevalence of anemia in HAART naïve
patients was 29.7% and on those patients on HAART
was 11.7%. This indicates that prevalence of anemia is
higher in treatment naïve patients (P < 0.001). This is
consistent with study done in Ghana [17] and US [18].
The findings of this study affirm that hematological
disorders are corrected by combination antiretroviral
therapy which also decreases the viral load. Thus HIV
patients who were on HAART had greater numbers of
blood cells within six months of beginning treatment
and hematological disorders were corrected [19].
In this study normocytic normochromic anemia was
the dominant type (43.3%) of anemia. This is supported
by different studies in which normocytic-normochromic
anemia is the commonest type of anemia in HIV pa-
tients [3-5,7,8]. Findings in New Delhi (66.5%) [7] in
2002 and in Nigerians (64%) between June, 2002 to July,
2003 [16] showed normocytic- normochromic anemia
which supports this study findings.
In this study majority of HAART naïve patients
(48.9%) have normocytic-normochromic anemia while
about 58.8% patients developed macrocytic-normochro-
mic anemia (p < 0.001). This is probably due to the effect
of HAART which is responsible for the development of
macrocytosis.
The prevalence of anemia was significantly higher
(34.5%, P = 0.011) in patients with CD4 count < 200/μl.
Table 4 Type of anemia among HIV patients attending Gondar University Hospital from February to May 2012
Type of anemia On HAART HAART naïve Total P-value
Microcytic-hypochromic 1 (5.9%) 5 (11.6%) 6 (10%) <0.001
Microcytic-normochromic 0 1 (2.3%) 1 (1.7%)
Normocytic-normochromic 5 (29.4%) 21 (48.9%) 26 (43.3%)
Normocytic-hypochromic 0 14 (32.6%) 14 (23.3%)
Macrocytic-hypochromic 1 (5.9%) 0 1 (1.7%)
Macrocytic-normochromic 10 (58.8%) 1 (2.3%) 11 (18.3%)
Macrocytic-hyperchromic 0 1 (2.3%) 1 (1.7%)
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study in Southern India [13] 64% and Brazil 61.1%
[14] with CD4 count < 200/μl. Patients with CD4
count <200/μl may have low immunity. This may be
caused by direct and indirect effect of HIV infection
(viral load), opportunistic infections, and toxicity of
the drugs [3,20].
Leucopenia prevalence in this study was 26.6% which was
higher than the prevalence in studies done in Nigeria from
2000–2005 [15] and from 2002 – 2003 [16] which showed
prevalence of 5.88%, 16.1% and 10% respectively. Another
study at the HIV clinic of Lagos [4] showed similar findings
in leucopenia (26.8%). In the present study, prevalence ofTable 5 CD4 counts and cytopenias in HIV patients at Gondar
Parameters
<200
N (%)
HIV patients
Anemia 20 (34.5%)
Leucopenia 25 (43.1%)
Thrombocytopenia 9 (15.5%)
Neutropenia 13 (22.4%)
Lymphopenia 4 (6.9%)
Patients on HAART
Anemia 3 (15.8%)
Leucopenia 12 (63.2%)
Thrombocytopenia 2 (10.5%)
Neutropenia 6 (31.6%)
Lymphopenia 2 (10.5%)
Pre-HAART patients
Anemia 17 (43.6%)
Leucopenia 13 (33.3%)
Thrombocytopenia 7 (17.9%)
Neutropenia 7 (17.9%)
Lymphopenia 2 (5.1%)
Note: Numerical data in Bold = indicates the level of significance (p < 0.05) (Chi squneutropenia and lymphopenia was 21.4% and 2.1% respect-
ively, which is lower than is reported in a study done in
Nigeria between 1995 and 2000 in which 64.4% and
40% presented with lymphopenia and neutropenia
respectively [21]. This difference may be due to variation
in study populations, clinical conditions and study design
methods.
Patients on HAART showed statistically significant in-
crease in leucopenia and neutropenia compared to their
HAART-naïve counterparts (p < 0.01). Similarly when
patient’s CD4 count decreases prevalence of leucopenia
and lymphopenia increases (p < 0.05). This may be due
to suppression of bone marrow and direct infection of TUniversity Hospital from February – May 2012
CD4 counts P-value
200-350 >350
N (%) N (%)
13 (14.8%) 27 (18.8%) 0.011
29 (33.0%) 22 (15.3%) <0.001
5 (5.7%) 5 (3.5%) 0.007
24 (27.3%) 25 (17.4%) 0.2
1 (1.1%) 1 (0.7%) 0.015
7 (14.6%) 7 (9%) 0.535
21 (43.8%) 19 (24.4%) 0.003
3 (6.2%) 1 (1.3%) 0.129
17 (35.4%) 18 (23.1%) 0.309
1 (2.1%) 0 0.015
6 (15%) 20 (30.3%) 0.021
8 (20%) 3 (4.5%) 0.001
2 (5%) 4 (6.1%) 0.07
7 (17.5%) 7 (10.6%) 0.479
0 1 (1.5%) 0.253
are test).
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naïve patients (26.9%, P = 0.013) than those on HAART
(13.1%). This condition reduces the body’s resistance to
many opportunistic infections and the patient becomes
more susceptible to bacterial infections and needs medical
attention, the condition may become life-threatening.
On the other hand prevalence of thrombocytopenia
(6.6%) in this study was lower than reports from a study
done in Lagos (16%) [4] and Nigeria between 2002 and
2003 (10%) [16]. This possible cause of thrombocyto-
penia may be due to immune destruction of platelets. It
is known that many chronic human diseases may have
an underlying autoimmune mechanism [22].
There was no significant difference in the prevalence
of thrombocytopenia between study participants on
HAART and those who are HAART-naïve. Thrombocy-
topenia, however, increases as CD4 decreases (p = 0.007).
Thrombocytopenia probably increases as immunological
incompetence worsens thus leading to increased risk of
excessive bleeding [9,10].
This study does not address iron status of study partic-
ipants hemoglobinopathies, inherited membrane disor-
ders and other nutritional deficiencies because of lack of
resources. Also the study focused only on comparisons
of hematological and immunological parameters but
does not addresses risk factors.
Conclusion
The commonest hematological abnormalities in the study
participants were anemia and leucopenia, especially neu-
tropenia. Prevalence of anemia was high in HAART naïve
patients while leucopenia and neutropenia prevalence
was higher in patients on HAART. Anemia, leucopenia,
thrombocytopenia and lymphopenia were increased as
CD4 count decreases. Based on the present finding, HIV
patients are recommended to check up their CD4 counts
regularly and to start HAART when it is appropriate in
order to decrease the prevalence of anemia.
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